Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Fibrogen Inc CS (NQ: FGEN )

11.69 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 11.69
Bid (Size) 11.62 (2)
Ask (Size) 12.09 (3)
Prev. Close 11.69
Today's Range 11.69 - 11.69
52wk Range 11.14 - 57.21
Shares Outstanding 92,621,941
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
From GlobeNewswire News Releases
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe 
From GlobeNewswire News Releases

Performance

YTD
-68.89%
-68.89%
1 Month
-3.47%
-3.47%
3 Month
-57.98%
-57.98%
6 Month
-65.65%
-65.65%
1 Year
-73.12%
-73.12%

More News

Read More
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
From PR Newswire
First Week of FGEN January 2024 Options Trading
Tags Stocks
From Market News Video
Land This Bargain Even Cheaper Than Chief Commercial Officer Wettig Did
Tags Stocks
From Market News Video
FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial
Tags Small Cap Biotech News
From Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Tags Health Care european medical agency FDA
From Benzinga
NASDAQ: FGEN Long Term Investor Alert: Investigation of Potential Wrongdoing at FibroGen, Inc.
From SBWire - Latest Press Releases
Thinking about buying stock in Geovax Labs, Marker Therapeutics, Agile Therapeutics, FibroGen, or Pixelworks?
From PR Newswire
A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings; Crude Oil Edges Lower
Tags ROST Eurozone News
From Benzinga
Here's What Recent News From the FDA Means for AstraZeneca
Tags Market News ALPMY FGEN
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.